Some people already manage diet, exercise regularly and receive lipid-lowering therapy, yet blood tests still show LDL (low-density lipoprotein cholesterol) above the target set by their clinician.
For people with higher cardiovascular risk, markedly elevated LDL, or insufficient response to current therapy, clinicians may also assess whether a long-acting cholesterol injection is appropriate. One approach uses siRNA (small interfering RNA) acting on liver pathways related to PCSK9; after the initiation phase, maintenance dosing is typically less frequent.
Key points: High LDL is linked to atherosclerosis and cardiovascular risk; targets should follow personal risk, not a single lab flag. Long-acting siRNA therapy can reduce PCSK9-related messaging in the liver so more LDL receptors keep clearing blood LDL; maintenance is often about every 6 months. Suitability and combination with current therapy need in-person clinician assessment.
Why is LDL called “bad cholesterol”?
LDL (low-density lipoprotein) carries cholesterol around the body. When blood LDL stays high for a long time, cholesterol may deposit in vessel walls and relate to atherosclerosis and later cardiovascular risk.
For people who already have cardiovascular disease or belong to higher-risk groups, the focus is often not only whether a lab report shows a red flag, but setting an LDL goal that fits personal history and overall risk. If high blood pressure or diabetes is also present, clinicians usually include those conditions in risk assessment; you can start with the weight-management clinic or read more in the Health Library.
How does a long-acting cholesterol injection work?
Think of the liver as a cholesterol recycling centre. Liver cells have LDL receptors that act like “recyclers”, bringing LDL from the blood back to the liver.
A protein called PCSK9 can affect how LDL receptors are recovered and reused. When fewer receptors are available, the liver’s ability to clear blood LDL is reduced.
One long-acting approach uses siRNA to lower PCSK9-related messaging in the liver so more LDL receptors keep working and blood LDL clearance increases. In short: less PCSK9 → more chance to reuse LDL receptors → greater hepatic clearance → lower blood LDL.
Does siRNA change DNA?
siRNA does not rewrite human DNA and is not the same as gene therapy.
It mainly acts on a specific intracellular messaging step that reduces production of a particular protein, so it should not be understood as “editing genes”.
How much can LDL fall?
Large phase 3 studies show that, on top of existing lipid-lowering therapy, this class of long-acting siRNA treatment targeting PCSK9-related pathways can further lower LDL substantially.
Baseline LDL, prior therapy, lifestyle, disease status and individual response differ, so the degree of reduction varies. A single “how much will one dose drop” figure should not decide care; clinicians weigh cardiovascular risk and LDL goals together.
How often is it given?
A common schedule is: first dose → another dose at 3 months → then about every 6 months.
In maintenance, that often means twice a year; the actual plan follows clinical assessment and follow-up arrangements.
Who may need further assessment?
Do not rely on one health-check number alone. Clinicians usually combine age, blood pressure, glucose, smoking history, kidney function, family history and existing cardiovascular disease when judging whether more intensive LDL control is needed.
Situations often discussed for possible assessment of a long-acting cholesterol injection (still individual clinical judgement) include:
- Prior myocardial infarction, coronary disease, ischaemic stroke or peripheral artery disease
- Familial hypercholesterolaemia, or persistently markedly high LDL
- Diet already adjusted and tolerable lipid-lowering therapy still not reaching the clinician’s LDL goal
- Risk stratification that calls for more intensive LDL control
- People suited to a longer-acting, lower-frequency injection follow-up plan
If chronic kidney disease or other internal-medicine issues are also present, you may also read early kidney disease signs and tests and discuss an overall follow-up plan at the weight-management clinic.
How do oral lipid-lowering medicines compare with long-acting injections?
The two approaches are not mutually exclusive. Many people still start with diet, activity and oral lipid-lowering therapy; long-acting injections are often considered when risk is higher or current therapy remains insufficient. The table below summarises common differences for quick review before a visit:
| Comparison | Traditional oral lipid-lowering therapy | Long-acting cholesterol injection (siRNA / PCSK9-related) |
|---|---|---|
| Typical context | Foundation option for many with high lipids and cardiovascular risk | When current therapy misses targets, or higher-risk people need further assessment |
| Concept of action | Depends on pharmacological class; helps lower blood lipids | Reduces PCSK9-related messaging in the liver and supports LDL-receptor reuse |
| Frequency concept | Usually regular oral dosing as prescribed | After initiation, maintenance often uses lower-frequency injections |
| Who may need adjustment | Intolerance, missed LDL goals, rising risk | Higher risk, familial hypercholesterolaemia, difficulty reaching goals |
| Shared principle | Needs clinician review of history, medicines and labs | Do not decide on a single red-flag result alone |
What discomfort may occur?
One common adverse effect is injection-site reaction such as redness, swelling, pain, itch or local rash.
In large trials these reactions were often mild to moderate and short-lived. History, medicines and labs still need clinician review before treatment.
If LDL falls, does that guarantee fewer heart attacks or strokes?
As of September 2026, large studies support sustained LDL lowering with this class of long-acting siRNA therapy.
However, “LDL reduction” and “proven reduction in myocardial infarction, stroke or cardiovascular death” are different levels of evidence. Large outcome trials for major cardiovascular events are still ongoing; LDL reduction should not be treated as an equal proportional drop in event risk.
Lifestyle change, comorbidity control and regular follow-up remain essential parts of overall cardiovascular risk management.
Ruian Clinic reminder: cholesterol care is more than a red flag
Cholesterol care should return to risk stratification and personalised goals. Bring recent blood results and a current medicine list so the clinician can assess thoroughly.
Taichung Ruian Clinic’s weight-management clinic can help with lipid and related metabolic assessment; you can also browse the Health Library for more full-length health articles. Any treatment choice should follow in-person clinician evaluation.
No. siRNA-based therapy mainly affects messaging for making a specific protein inside cells; it does not rewrite human DNA and should not be equated with gene therapy. Suitability still needs clinician assessment.
Not necessarily. Many people continue oral therapy with diet and activity. If risk is higher, LDL stays off target, or a lower-frequency maintenance plan is being discussed, a clinician can assess whether a long-acting injection is appropriate to add.
Maintenance is often about every 6 months (twice yearly), but initiation usually includes a first dose and a 3-month dose. Exact frequency and follow-up follow individual plans.
That is not how it should be understood. Studies support sustained LDL lowering, but LDL change and proven reduction in major cardiovascular events are different layers of evidence. Outcome trials continue, and lifestyle plus comorbidity care remain important.
Redness, swelling, pain, itch or local rash are relatively common and often mild to moderate and brief. If symptoms worsen, persist or come with other problems, seek prompt review.
No—do not decide from a single red flag. Clinicians review overall cardiovascular risk, history, current therapy and lifestyle before setting LDL goals and next steps. Bring reports and medicine lists to the visit.
Doctor’s note: cholesterol control looks at overall risk, not one blood test
Whether LDL needs more intensive treatment usually considers age, blood pressure, glucose, weight and metabolic status, family history, and prior cardiovascular disease. If lipids stay high on checks, or therapy has not reached your personal goal, bring recent reports and medicine lists for assessment of options such as long-acting injection.
This article is disease education, not a drug advertisement, and does not promote or sell any specific medicine. It cannot replace in-person diagnosis or prescribing; whether a long-acting cholesterol injection is needed requires clinician assessment for the individual.
Weight-management medical team
Dr. Tseng
